Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3216 Carcinoma, Non-Small-Cell Lung 2729 Breast Neoplasms 2551 Colorectal Neoplasms 1463 Prostatic Neoplasms 1307 Neoplasm Metastasis 1301 Multiple Myeloma 1112 Melanoma 1103 Ovarian Neoplasms 1006 Lung Neoplasms 945 Recurrence 924 Leukemia, Myeloid, Acute 879 Pancreatic Neoplasms 833 Lymphoma, Non-Hodgkin 767 Lymphoma 713 Stomach Neoplasms 692 Carcinoma, Renal Cell 660 Carcinoma, Hepatocellular 647 Leukemia, Lymphocytic, Chronic, B-Cell 560 Squamous Cell Carcinoma of Head and Neck 550 Lymphoma, Follicular 515 Head and Neck Neoplasms 490 Glioblastoma 473 Small Cell Lung Carcinoma 447 Lymphoma, Large B-Cell, Diffuse 440 Triple Negative Breast Neoplasms 436 Advanced Solid Tumors 432 Leukemia 426 Uterine Cervical Neoplasms 420 Urinary Bladder Neoplasms 405

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡